Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
NCT: NCT06790784 · RECRUITING
광고
NCT IDNCT06790784
상태RECRUITING
시작일2025-08-04
SponsorJaeb Center for Health Research (OTHER)
First posted
Last updated
간략 요약
This randomized trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser. The participants will be followed for 3 years. The study will evaluate long-term visual acuity as well as differences in number of injections, procedures, and complications during follow-up (after completion of randomization treatment), and cost.
공식 출처
ClinicalTrials.gov에서 보기 →데이터는 ClinicalTrials.gov API에서 제공됩니다. 최신 상태는 공식 기록을 확인하세요.